2 recruiting, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Allogeneic NK cells: new trials by email Literature Review of Allogeneic NK cells trials Research Report on Allogeneic NK cells
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. Allogeneic NK Cells - Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) | Phase 2 | Recruiting | Artiva Biotherapeutics, Inc. | 90 | 2025-07-09 | 2026-07-31 |
| Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor Allogeneic NK cells - Malignant Lymphomas, Solid Tumors | Phase 1 | Completed | Seoul National University Hospital | 18 | 2010-09-01 | 2013-08-19 |
Arthritis, Rheumatoid (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myositis (1) · Scleroderma, Diffuse (1) · Scleroderma, Systemic (1) · Sjogren's Syndrome (1)
Artiva Biotherapeutics, Inc. (1) · Paolo Caimi, MD (1) · Seoul National University Hospital (1)
United States (2) · Brazil (1) · Bulgaria (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Portugal (1) · Romania (1) · Serbia (1) · South Korea (1) · Spain (1)
Michael Saddekni, M.D., PgDip, BCMAS (1) · Paolo Caimi, MD (1)